Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Newsletter subscription
Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Languages
ENGLISH
English (US)
ASIAN
Монгол
日本語
Tiếng Việt
Bahasa Indonesia
中文 (简体, 中国大陆)
EUROPEAN
Русский
Español (España)
Français (France)
MIDDLE_EAST_AFRICA
العربية
Search results for "Celltrion"
Home
Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4 clinical trial of Zymfentra...
09/21/2026, 21:51 ET
Celltrion Targets 33% Shareholder Payout Ratio, Adds 100 Billion Won Share Buyback
Celltrion announced on Aug. 31 that it will return approximately one-third of its annual consolidated net profit to shareholders moving forward...
09/21/2026, 02:10 ET
Celltrion to Select Japanese Biotech Startups for Joint R&D and Pipeline Expansion
Celltrion is stepping up efforts to identify and foster promising biotech startups in Japan.
09/13/2026, 10:33 ET
Zymfentra U.S. Sales Surge 176% as Celltrion’s Remsima Franchise Eyes 1 Trillion Won Annual Revenue
Biopharmaceutical company Celltrion announced on Aug. 27 that combined first-half sales of its subcutaneous infliximab...
09/02/2026, 05:15 ET
Celltrion Files for South Korean Approval of Keytruda Biosimilar CT-P51
Celltrion announced on August 24 that it has submitted a marketing authorization application to South Korea’s Ministry...
08/28/2026, 23:36 ET
Celltrion Secures Dominant Market Share in Asia Led by Autoimmune and Oncology Biosimilars
Celltrion is consolidating its leading market position across major Asian countries with its key autoimmune and...
08/20/2026, 01:54 ET
Celltrion Chairman Seo Jung-jin Forgoes Summer Vacation for Global Business Tour Targeting Record Second Half
Celltrion Group Chairman Seo Jung-jin will forgo his summer vacation this August to embark on an intensive overseas...
08/12/2026, 23:19 ET
Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market
Celltrion announced on the 24th that it has submitted a marketing authorization application to the European Medicines...
07/27/2026, 05:13 ET
Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68
Celltrion announced on July 15 that it has received approval from South Korea’s Ministry of Food and Drug Safety for an...
07/16/2026, 04:14 ET
Landmark Biotech Deal: Celltrion Acquires Autoimmune Disease Antibody Tech from Catholic University of Korea
A research team led by Kim Wan-wook at the Catholic University of Korea College of Medicine has successfully...
07/15/2026, 00:33 ET
1
2
3
Next